2 results
Approved WMOPending
To assess the efficacy of add-on high-dose simvastatin on markers for disease progression in MS patients treated with natalizumab or ocrelizumab for at least six months.
Approved WMORecruiting
The main objective of this study is to assess the safety of combining Nivolumab with IRE alone and of combining Nivolumab with IRE and CpG .The secondary objectives of this study are : 1) whether the combination of Nivolumab + IRE, or of CpG +…